METHOD FOR IN VIVO DETERMINATION ON TESTED ANIMALS OF THE EFFICIENT CONCENTRATION OF DEUTERIUM DEPLETED WATER FOR CANCER THERAPY

WIPO Patent Application WO2005017522

B1

As per invention embodiment, the method provides Deuterium Depleted Water administering to tested animals before and after tumoral grafting with animal grafts and it takes the following steps: A) Deuterium Depleted Water administering to Wistar outbred rats by diet, with concentrations of 25 ppm D2, 60 ppm D2, and 100 ppm D2, over a period of 60 days, simultaneously to dieting a control group of animals with water having 150 ppm content of Deuterium (tap water), over the same period of time. B) Viability determination for the tumor cells to be grafted, using tripan blue C) Grafting of the animals in the experimental group and the control animals in the 60 day, subcutaneous, with 1 x 10<7> malign tumor cells in 0.5 cc of normal saline solution of 256 Walker sarcoma (the solid tumor), and T8 Guérin lymphotropic epitelioma (the solid tumor) both of them having cells with a viability over 98%. D) Continuously and long-term administering, by diet, of Deuterium Depleted Water, with concentrations of 25 ppm, 60 ppm, 100 ppm Deuterium, period over which the followings are to be done: a. Starting with the 4post-graft day the tumor nodules measurement and examination is performed on each 2-3 days; b. Monitoring of animals' physiological condition by weekly weighing, monitoring their food and water consumption, notifying the toxic condition occurrence c. After 60 days, when all the animals in control group are dead, preferable between the 160 and 200 day after graft, the effect produced by administering of established concentrations of Deuterium Depleted Water is observed on the surviving animals homeostasis from experimental groups, respectively the way how humoral immune system and cellular immune system of these animals has been influenced, by performing of a series of examination on immunological condition of the animals, namely: leucocytes formula test to establish lymphocytes and blastic cells levels; hematopoietic marrow tests to establish the plasmocytes and NK-K cells levels. Also, was established the level of the competent immunologic cells in the lymph nods of the tumoral graft zona. E) Determination of efficient concentration of Deuterium Depleted Water for tested surviving animals depending on new homeostasis occurrence, and on the results obtained related to<,> tumoral regression, as well as on cancer curing cases. This method determines the 60 ppm concentration of Deuterium Depleted Water to be the most efficient for cancer therapy and prophylaxis by continuously and long-term administering of this type of water in daily diet.

MANOLESCU NICOLAE (RO)
BALANESCU ION (RO)
VALECA SERBAN CONSTANTIN (RO)
TRAICU RODIN (RO)
MARCULESCU DUMITRU (RO)
NICULITA PETRU (RO)
STEFANESCU IOAN (RO)
TERBEA IOAN (RO)
MORARU VICTORIA (RO)
COMISEL VIRGILIU (RO)
MATEESCU CORNELIU (RO)
ENCUT IOAN (RO)
PANAIT MARIETA (RO)
BEGU DANIELA (RO)
CINCA SABIN (RO)
GRUIA MARIA-IULIANA (RO)
BALINT EMILIA (RO)
POP ANETA (RO)

PCT/RO2004/000012

June 16, 2005

July 20, 2004

Click for automatic bibliography generation  

INST ONCOLOGIC PROF DR AL TRES (RO)
MANOLESCU NICOLAE (RO)
BALANESCU ION (RO)
VALECA SERBAN CONSTANTIN (RO)
TRAICU RODIN (RO)
MARCULESCU DUMITRU (RO)
NICULITA PETRU (RO)
STEFANESCU IOAN (RO)
TERBEA IOAN (RO)
MORARU VICTORIA (RO)
COMISEL VIRGILIU (RO)
MATEESCU CORNELIU (RO)
ENCUT IOAN (RO)
PANAIT MARIETA (RO)
BEGU DANIELA (RO)
CINCA SABIN (RO)
GRUIA MARIA-IULIANA (RO)
BALINT EMILIA (RO)
POP ANETA (RO)

A61K41/00; A61K49/00; G01N1/28; G01N33/50; (IPC1-7): G01N33/15; A61K49/00

View/Download PDF      PDF Help

Previous Patent: TECHNIQUES FOR RECORDING SIGNALS

Next Patent: METHOD FOR DISCRIMINATING BETWEEN ISCHEMIC AND HAEMORRHAGIC STROKE